Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2006 5
2007 5
2008 11
2009 10
2010 29
2011 47
2012 70
2013 107
2014 131
2015 128
2016 76
2017 122
2018 107
2019 132
2020 124
2021 111
2022 124
2023 108
2024 35

Text availability

Article attribute

Article type

Publication date

Search Results

1,262 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "BRAF Protein Variant"
Page 1
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.
Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong TG, Moon HH, Davar D, O'Rourke M, Stephenson JJ, Curti BD, Urba WJ, Brell JM, Funchain P, Kendra KL, Ikeguchi AP, Jaslowski A, Bane CL, Taylor MA, Bajaj M, Conry RM, Ellis RJ, Logan TF, Laudi N, Sosman JA, Crockett DG, Pecora AL, Okazaki IJ, Reganti S, Chandra S, Guild S, Chen HX, Streicher HZ, Wolchok JD, Ribas A, Kirkwood JM. Atkins MB, et al. J Clin Oncol. 2023 Jan 10;41(2):186-197. doi: 10.1200/JCO.22.01763. Epub 2022 Sep 27. J Clin Oncol. 2023. PMID: 36166727 Free PMC article. Clinical Trial.
PURPOSE: Combination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4-blockade and dual BRAF/MEK inhibition have each shown significant clinical benefit in patients with BRAFV600-mutant metastatic melanoma, leading to broad regulatory appr …
PURPOSE: Combination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4-blockade and dual BRAF/MEK inhibition have …
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.
Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Elez E, Gollerkeri A, Maharry K, Christy-Bittel J, Kopetz S. Tabernero J, et al. J Clin Oncol. 2021 Feb 1;39(4):273-284. doi: 10.1200/JCO.20.02088. J Clin Oncol. 2021. PMID: 33503393 Free PMC article. Clinical Trial.
The purpose of this analysis was to report updated efficacy and safety data. METHODS: In this open-label, phase III trial, 665 patients with BRAF V600E-mutant mCRC were randomly assigned 1:1:1 to receive triplet, doublet, or control. ...Based on the pr …
The purpose of this analysis was to report updated efficacy and safety data. METHODS: In this open-label, phase III trial, 665 patien …
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF(V600E)-Mutant Colorectal Cancer.
Corcoran RB, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Middleton G, Muro K, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, Humblet Y, De Vos F, Jung AS, Brase JC, Jaeger S, Bettinger S, Mookerjee B, Rangwala F, Van Cutsem E. Corcoran RB, et al. Cancer Discov. 2018 Apr;8(4):428-443. doi: 10.1158/2159-8290.CD-17-1226. Epub 2018 Feb 5. Cancer Discov. 2018. PMID: 29431699 Free PMC article. Clinical Trial.
Although BRAF inhibitor monotherapy yields response rates >50% in BRAF(V600)-mutant melanoma, only approximately 5% of patients with BRAF(V600E) colorectal cancer respond. ...This clinical trial evaluated BRAF and EGFR inhibitio …
Although BRAF inhibitor monotherapy yields response rates >50% in BRAF(V600)-mutant melanoma, only approximately 5% …
NRAS mutant melanoma: Towards better therapies.
Randic T, Kozar I, Margue C, Utikal J, Kreis S. Randic T, et al. Cancer Treat Rev. 2021 Sep;99:102238. doi: 10.1016/j.ctrv.2021.102238. Epub 2021 May 29. Cancer Treat Rev. 2021. PMID: 34098219 Free article. Review.
Genetic alterations affecting RAS proteins are commonly found in human cancers. Roughly a fourth of melanoma patients carry activating NRAS mutations, rendering this malignancy particularly challenging to treat. Although the development of targeted as well as immunotherapi …
Genetic alterations affecting RAS proteins are commonly found in human cancers. Roughly a fourth of melanoma patients carry activatin …
The role of BRAF V600 mutation in melanoma.
Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, Palmieri G, Testori A, Marincola FM, Mozzillo N. Ascierto PA, et al. J Transl Med. 2012 Jul 9;10:85. doi: 10.1186/1479-5876-10-85. J Transl Med. 2012. PMID: 22554099 Free PMC article.
BRAF is a serine/threonine protein kinase activating the MAP kinase/ERK-signaling pathway. ...The first selective inhibitor of mutant BRAF, vemurafenib, after highly encouraging results of the phase I and II trial, was compared to dacarbazine in …
BRAF is a serine/threonine protein kinase activating the MAP kinase/ERK-signaling pathway. ...The first selective inhibitor of …
Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma.
Bouffet E, Geoerger B, Moertel C, Whitlock JA, Aerts I, Hargrave D, Osterloh L, Tan E, Choi J, Russo M, Fox E. Bouffet E, et al. J Clin Oncol. 2023 Jan 20;41(3):664-674. doi: 10.1200/JCO.22.01000. Epub 2022 Nov 14. J Clin Oncol. 2023. PMID: 36375115 Free PMC article. Clinical Trial.
PURPOSE: BRAF V600 mutations occur in many childhood cancers, including approximately 20% of low-grade gliomas (LGGs). ...Age-based and weight-based dosing of trametinib with or without dabrafenib achieved target concentrations with manageable safety and demonstrated cl …
PURPOSE: BRAF V600 mutations occur in many childhood cancers, including approximately 20% of low-grade gliomas (LGGs). ...Age-based a …
Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era.
Goyal G, Heaney ML, Collin M, Cohen-Aubart F, Vaglio A, Durham BH, Hershkovitz-Rokah O, Girschikofsky M, Jacobsen ED, Toyama K, Goodman AM, Hendrie P, Cao XX, Estrada-Veras JI, Shpilberg O, Abdo A, Kurokawa M, Dagna L, McClain KL, Mazor RD, Picarsic J, Janku F, Go RS, Haroche J, Diamond EL. Goyal G, et al. Blood. 2020 May 28;135(22):1929-1945. doi: 10.1182/blood.2019003507. Blood. 2020. PMID: 32187362 Free article. Review.
With the recent molecular discoveries and the approval of the first targeted therapy (vemurafenib) for BRAF-V600-mutant ECD, there is a need for updated clinical practice guidelines to optimize the diagnosis and treatment of this disease. This document presen …
With the recent molecular discoveries and the approval of the first targeted therapy (vemurafenib) for BRAF-V600-mutant ECD, t …
Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer.
Fois SS, Paliogiannis P, Zinellu A, Fois AG, Cossu A, Palmieri G. Fois SS, et al. Int J Mol Sci. 2021 Jan 9;22(2):612. doi: 10.3390/ijms22020612. Int J Mol Sci. 2021. PMID: 33435440 Free PMC article. Review.
Testing the presence of driver mutations in specific genes in lung tumors has thus radically changed the clinical management and outcomes of the disease. Numerous studies performed with traditional sequencing methods have investigated the occurrence of such mutations in lu …
Testing the presence of driver mutations in specific genes in lung tumors has thus radically changed the clinical management and outc …
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B. Subbiah V, et al. J Clin Oncol. 2018 Jan 1;36(1):7-13. doi: 10.1200/JCO.2017.73.6785. Epub 2017 Oct 26. J Clin Oncol. 2018. PMID: 29072975 Free PMC article. Clinical Trial.
Purpose We report the efficacy and safety of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) combination therapy in BRAF V600E-mutated anaplastic thyroid cancer, a rare, aggressive, and highly lethal malignancy with poor patient outcomes and no systemic t …
Purpose We report the efficacy and safety of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) combination therapy in BRA …
Dabrafenib.
Kainthla R, Kim KB, Falchook GS. Kainthla R, et al. Recent Results Cancer Res. 2014;201:227-40. doi: 10.1007/978-3-642-54490-3_14. Recent Results Cancer Res. 2014. PMID: 24756796 Review.
Dabrafenib was developed as a highly specific reversible inhibitor of V600-mutant BRAF kinase, an oncogenic mutation driving proliferation in many different types of aggressive tumors. Metastatic melanoma has a high prevalence of V600-mutant BRAF, and …
Dabrafenib was developed as a highly specific reversible inhibitor of V600-mutant BRAF kinase, an oncogenic mutation driving p …
1,262 results